SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : dsco Discovery Laboratories
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (131)9/30/2007 4:48:29 PM
From: detlef gerlach  Read Replies (1) of 318
 
No doubt Surfaxin will put a dent usage of Survanta and Curosurf--again, if it passes stability parameters. So far so good. I think if the preliminary tests had been problematic, DSCO would have been obligated to report this. Within the next month they should submit data to the FDA. Hopefully, the FDA will accept the results without question
Surfaxin is the only surfactant that has shown efficacy in the prevention of BPD. This in itself will encourage neonatologists to switch.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News